Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8213140 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 29 Pages |
Abstract
Patients with high-risk neuroblastoma in this series maintained excellent local control, with no benefit demonstrated for radiation doses over 21.6Â Gy, and no disadvantage demonstrated for gross residual disease after surgery, positive surgical margins, or pathologic lymph node positivity. Though the limitations of a retrospective review for an uncommon disease must be kept in mind, with small numbers in some of the subgroups, it seems that dose escalation should be considered only in exceptional circumstances.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Matthew J. MD, Hasan MD, Jeffrey M. PhD, Claudia BS, Bradley A. MD, Kelly C. MD, Karen J. MD, W. Thomas MD, Mohammad K. MD, PhD, Bree R. MD, Natia MD,